News Related to Tulisokibart

Related coverage linked through entity extraction aliases.

Barclays Initiates Merck Coverage with Overweight Rating on 2026 Drug Pipeline

Feb 20, 2026

Barclays initiated coverage on Merck with an overweight rating and $140 price target, citing expected product launches including enlicitide and pivotal trial readouts for tulisokibart in 2026.

Merck Stock Surges 46% to 52-Week High on Post-Keytruda Pipeline Strength

Feb 13, 2026

Merck stock reached a 52-week high at $122.69, rising 46.25% over 12 months and 7.4% in the past month following strong Q4 results and improved long-term pipeline outlook beyond Keytruda's 2028 patent expiration.